Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoon Sim Yap

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Frontiers in Oncology|August 2, 2021
Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast CancerSay Li Kong, Xingliang Liu, Swee Jin Tan, et al.
Breast Cancer (Tokyo, Japan)|June 24, 2026
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trialTakashi Yamanaka, Joohyuk Sohn, Kazuki Sudo, et al.
Clinical Pharmacology and Therapeutics|January 11, 2023
Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma ConcentrationsChiea Chuen Khor, Stefan Winter, Natalia Sutiman, et al.
NPJ Breast Cancer|January 28, 2026
Outcomes of a prospective cohort study of PREoperative therapy and supportive care in early & locally advanced breast cancers-PreSCella studyHan Yi Lee, Whee Sze Ong, Jasmine Yun Ting Tan, et al.
NPJ Breast Cancer|August 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerEmi Noguchi, Takashi Yamanaka, Hirofumi Mukai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2020
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA TrialCristina Saura, Mafalda Oliveira, Yin-Hsun Feng, et al.
Nature Biomedical Engineering|March 7, 2025
A deep-learning model for quantifying circulating tumour DNA from the density distribution of DNA-fragment lengthsGuanhua Zhu, Chowdhury Rafeed Rahman, Victor Getty, et al.
JCO Precision Oncology|July 12, 2021
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center ExperienceAmanda O L Seet, Aaron C Tan, Tira J Tan, et al.
Science Advances|October 6, 2021
Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancerSer Yue Loo, Li Ping Toh, William Haowei Xie, et al.
The New England Journal of Medicine|October 9, 2016
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Frontiers in Oncology|August 2, 2021
Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast CancerSay Li Kong, Xingliang Liu, Swee Jin Tan, et al.
Breast Cancer (Tokyo, Japan)|June 24, 2026
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trialTakashi Yamanaka, Joohyuk Sohn, Kazuki Sudo, et al.
Clinical Pharmacology and Therapeutics|January 11, 2023
Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma ConcentrationsChiea Chuen Khor, Stefan Winter, Natalia Sutiman, et al.
NPJ Breast Cancer|January 28, 2026
Outcomes of a prospective cohort study of PREoperative therapy and supportive care in early & locally advanced breast cancers-PreSCella studyHan Yi Lee, Whee Sze Ong, Jasmine Yun Ting Tan, et al.
NPJ Breast Cancer|August 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerEmi Noguchi, Takashi Yamanaka, Hirofumi Mukai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2020
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA TrialCristina Saura, Mafalda Oliveira, Yin-Hsun Feng, et al.
Nature Biomedical Engineering|March 7, 2025
A deep-learning model for quantifying circulating tumour DNA from the density distribution of DNA-fragment lengthsGuanhua Zhu, Chowdhury Rafeed Rahman, Victor Getty, et al.
JCO Precision Oncology|July 12, 2021
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center ExperienceAmanda O L Seet, Aaron C Tan, Tira J Tan, et al.
Science Advances|October 6, 2021
Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancerSer Yue Loo, Li Ping Toh, William Haowei Xie, et al.
The New England Journal of Medicine|October 9, 2016
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
Pageof 10